|Bid||249.80 x 300|
|Ask||250.80 x 100|
|Day's Range||250.51 - 253.61|
|52 Week Range||223.02 - 333.65|
|PE Ratio (TTM)||15.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.